The PANDA study: a randomized phase II study of first-line FOLFOX plus panitumumab versus 5FU plus panitumumab in RAS and BRAF wild-type elderly metastatic colorectal cancer patients

Overview of attention for article published in BMC Cancer, January 2018

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (80th percentile)
High Attention Score compared to outputs of the same age and source (84th percentile)

Mentioned by

blogs: 1 blog

twitter: 2 X users

Citations

dimensions_citation: 20 Dimensions

Readers on

mendeley: 52 Mendeley

Summary Blogs X Dimensions citations

So far, Altmetric has seen 2 X posts from 2 X users, with an upper bound of 1,134 followers.

RT @OncoHebdo: Résultats de l'étude de phase II PANDA évaluant FOLFOX + #panitumumab chez des patients âgés dans le cancer colorectal métas…

02 Feb 2018

Reply Repost Favourite

Résultats de l'étude de phase II PANDA évaluant FOLFOX + #panitumumab chez des patients âgés dans le cancer colorectal métastatique publiés dans BMC Cancer https://t.co/QIGOWRJjfV

02 Feb 2018

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.